A Study of Gastric Delay in Migraine Patients (3207-003)

Phase 1

Completed

• Conditions: Migraine Disorders
• Interventions: Drug: MK3207

• Registration Number: NCT00548353
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

A study to assess safety and PK of an investigational drug in migraine patients during and between migraine attacks.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-08
• Study First Submitted: 2007-10-19
• Study First Submitted QC: 2007-10-19
• Study First Posted: 2007-10-23
• Primary Completion: 2008-04
• Study Completion: 2010-02
• Status Verified: 2014-12
• Last Update Submitted: 2014-12-18
• Last Update Posted: 2014-12-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

• Non-smoking male or female between 18 to 45 years of age
• Patient typically has between 2 and 10 migraine attacks per month, rated as moderate or severe

Exclusion Criteria

• Patient has any other medical conditions other than migraine

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	MK3207	MK3207 Orally administered to patients with water. During each period (with and without acute migraine).

Primary Outcome Measures

Name	Time	Method
Safety in migraine patients	12 Weeks

Secondary Outcome Measures

Name	Time	Method
PK in migraine patients	12 Weeks